Toon Van Gorp, MD, PhD

home / authors / toon-van-gorp-md-phd

Toon Van Gorp, MD, PhD, a gynecologic oncologist at Universitair Ziekenhuis Leuven in Belgium.

Articles

Toon Van Gorp, MD, PhD

Dr Van Gorp on the Role of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

Toon Van Gorp, MD, PhD
April 3rd 2025

Toon Van Gorp, MD, PhD, discusses the significance of mirvetuximab soravtansine as treatment for FRα-positive, platinum-resistant ovarian cancer.

Read More

Toon Van Gorp, MD, PhD

Dr Van Gorp on the Long-Term Efficacy of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

Toon Van Gorp, MD, PhD
March 16th 2025

Toon Van Gorp, MD, PhD, discusses the efficacy of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian cancer after 30.5 months of follow-up.

Read More

Latest Updated Articles

Arielle Heeke, MD
Published: May 2nd 2025 | Updated: May 6th 2025
Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval
Vivek G Patel, MD
Published: April 2nd 2025 | Updated: May 2nd 2025
Dr Patel on Choosing Between Mosunetuzumab and Epcoritamab in Follicular Lymphoma
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer